Redefining Cancer Care: How AI is Revolutionizing the Future of Oncology – Insights from Dr. Marika Crohns

Keynote Speaker:

Dr. Marika Crohns, MD, PhD
Founder & CEO, Impactful Innovations Management Consultants LLC, Dubai, UAE
Session Type: Keynote Virtual Presentation

Title: Intelligent oncology: The transformative role of AI in the future of cancer research and care

---

💡 Presentation Highlights:

Artificial Intelligence (AI) is emerging as the next frontier in the battle against cancer — revolutionizing the way we diagnose, treat, and understand this complex disease. In her keynote talk, Dr. Marika Crohns explores how intelligent oncology is transforming the future of cancer research and patient care.

🔍 Key Takeaways:

·         AI-Powered Early Detection:
Machine learning and deep neural networks are identifying cancer earlier than traditional diagnostic methods, enabling faster intervention and improved outcomes.

·         Smarter Biomarker Discovery:
Advanced AI analytics are decoding genomic and proteomic data to discover new biomarkers, accelerating innovation in targeted drug development.

·         Personalized Treatment with Precision AI:
Predictive algorithms are optimizing patient stratification, allowing for highly individualized treatment plans tailored to each patient’s molecular profile.

·         Revolutionizing Clinical Trials:
Adaptive AI models are improving the efficiency and flexibility of clinical trial designs, reducing costs and increasing success rates.

·         Harnessing Real-World Data:
AI integration with electronic health records and wearable devices is enabling real-time analysis of treatment responses and long-term patient outcomes.

·         Addressing Ethical and Regulatory Challenges:
Dr. Crohns stresses the importance of ethical AI development — ensuring transparency, fairness, and data integrity in clinical applications.

·         The Road Ahead:
From federated learning for privacy-preserving data analysis to generative AI for hypothesis creation, the future of intelligent oncology is dynamic and transformative.

---

👩‍⚕️ About Dr. Marika Crohns:

Dr. Marika Crohns is an internationally recognized oncologist and thought leader in healthcare innovation.

·         Over 30 years of experience across academia, clinical medicine, and the pharmaceutical industry.

·         Former Vice President & Global Medical Head for Oncology, Hematology, and Transplant at Sanofi.

·         Holds MD and PhD degrees, with a PhD thesis on biomarkers in lung cancer.

·         Currently leads Impactful Innovations Management Consultants LLC, focusing on healthcare transformation and digital innovation.

·         Passionate advocate for women’s leadership and sustainability in healthcare.

---

🩺 Event Details:

Event: International Conference on Cancer Science and Research
📅 Dates: November 17–19, 2025
🏛️ Venue: Singapore and Online (Hybrid Event)
🌐 Website: https://cancer.miconferences.com
📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448 | 💬 WhatsApp: +1 (424) 377 0967
🐦 Follow: https://x.com/CancerWorldConf
🎤 Meet Our Speakers: https://cancer.miconferences.com/program/speakers/2025

---

#CancerConference #AIinOncology #OncologyInnovation #CancerResearch2025 #CancerScience #IntelligentOncology #AIHealthcare #PrecisionMedicine #DigitalOncology #CancerCare #HealthcareAI #CancerWorldConference #OncologyFuture #HybridConference #SingaporeConference #MedicalInnovation #AIRevolutionInMedicine

Exploring Immunological Predictors in Prostate Cancer: Dr. Sergey Reva’s Groundbreaking Insights

At the International Conference on Cancer Science and Research (November 17–19, 2025) in Singapore and Online, Dr. Sergey Reva from Pavlov First Saint Petersburg State Medical University, Russian Federation, presented an insightful study exploring the role of immunological markers as predictors of unfavorable outcomes in prostate cancer patients undergoing radical prostatectomy.

His research shed new light on how systemic inflammation markers — including Neutrophil-Lymphocyte Ratio (NLR), Platelet-Lymphocyte Ratio (PLR), and Lymphocyte-Monocyte Ratio (LMR) — could potentially indicate tumor aggressiveness and disease progression.

---

🔍 Key Takeaways from the Study

• 🧬 Systemic Inflammation in Cancer: The study reinforced that inflammation plays a crucial role in cancer development and progression, influencing tumor biology and patient outcomes.
• 📈 Clinical Analysis: Conducted on 74 prostate cancer patients treated with laparoscopic radical prostatectomy, with data collected on preoperative blood markers.
• 🔢 Significant Findings:
• Patients with NLR > 1.67 showed a higher risk of locally advanced disease (pT3 or higher) (p=0.0241).
• A PLR > 113.8 was linked to high-grade prostate cancer (ISUP 4–5) (p=0.0416).
• ⚖️ No Strong Correlation Found: Between these markers and postoperative features like upstaging, risk group increase, or lymph node involvement (p>0.05).
• 💡 Overall Conclusion: Elevated NLR and PLR values can be used as predictive indicators for more aggressive forms of prostate cancer, aiding in patient stratification and treatment planning.

---

👨‍⚕️ About the Researcher

Dr. Sergey Reva is a prominent oncologist and urologist, holding a PhD in Oncology from N.N. Petrov Research Institute of Oncology. He serves as the Chairman of the Urooncological Department at Pavlov First Saint Petersburg State Medical University. His main research interests revolve around prostate and bladder cancer, and he is affiliated with leading organizations like the European Association of Urology (EAU), Société Internationale d'Urologie (SIU), and American Urological Association (AUA).

With more than 20 scientific publications, Dr. Reva continues to contribute valuable insights to the field of uro-oncology and cancer immunology.

---

🌐 Conference Information

📅 Event: International Conference on Cancer Science and Research
📍 Venue: Singapore & Online
🔗 Website: https://cancer.miconferences.com/
📨 Email: cancer@mathewsconference.com
📱 Phone: +1 (312) 462-4448
💬 WhatsApp: +1 (424) 377 0967
📝 Registration: Click Here
🧾 Abstract Submission: Click Here
🐦 Follow Updates: @CancerWorldConf

---

🧩 #ProstateCancer #CancerScience2025 #CancerResearch #UroOncology #OncologyInsights #Immunology #CancerConference #SingaporeConference #CancerDiagnostics #CancerImmunology #InflammatoryMarkers 

Fiber-Optic Breakthroughs Shaping the Future of Cancer Diagnostics

Cancer detection is entering a new era with the use of fiber-optic technologies that enable faster, more accurate, and real-time diagnostics. At the International Conference on Cancer Science and Research (November 17–19, 2025 | Singapore & Online), Dr. Viacheslav Artyushenko from Art photonics GmbH, Germany, will showcase pioneering innovations in this field through his talk: “Innovative fiber solutions for cancer diagnostics.”

🌟 Key Insights from the Presentation

·         Multispectral Range (0.3–16µm): Covering the entire optical window for comprehensive tissue analysis.

·         Tumor Margin Definition: Real-time detection ex-vivo and in-vivo using IR-fiber and Raman endoscopy.

·         Integration of Multiple Modalities: Combining NIR, MIR, Raman, and Fluorescence spectroscopy in compact probes.

·         Disposable Raman Needle Probes: Ultra-thin (<200 µm) single-fiber tools enabling rapid oral cancer detection during surgery.

·         Fusion of Spectroscopy Data: Synergistic results achieved by combining fluorescence with MIR/NIR methods.

·         Towards Mid-IR Endoscopy: PIR-fiber catheters open the door to detecting cancers in hollow organs.

👨‍🔬 About Dr. Viacheslav Artyushenko

Dr. Artyushenko, PhD in Physics, is a pioneer in polycrystalline fiber technology for Mid-IR (3–18µm). In 1998, he founded Art photonics GmbH, a global leader in specialty fiber optics for industrial, scientific, and medical applications. With numerous patents and scientific contributions, he continues to drive advancements in spectroscopy and biomedical diagnostics.

📌 International Conference on Cancer Science and Research – Event Details

📅 Dates: November 17–19, 2025
📍 Venue: Singapore & Online (Hybrid Event)
🌐 Conference Website: https://cancer.miconferences.com/
📝 Abstract Submission Link: Click Here
✅ Registration Link: Click Here

📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448
💬 WhatsApp: +1 (424) 377 0967
🐦 X: @CancerWorldConf

---

#CancerResearch #FiberOptics #BiomedicalInnovation #CancerDiagnostics #Spectroscopy #CancerConference2025 #OncologyTechnology #MedicalBreakthroughs

Breakthrough Talk: Resveratrol’s Impact on Acute Promyelocytic Leukemia

At the upcoming Cancer Conference 2025, Dr. Minoo Shahidi from the Iran University of Medical Sciences will present her latest findings on the role of Resveratrol (RSV) in reducing the formation of extracellular traps (ETs) in acute promyelocytic leukemia (NB4) cells. ETosis and NETosis, which drive cancer progression, metastasis, and thrombosis, are increasingly seen as potential therapeutic targets. Dr. Shahidi’s study focuses on how Resveratrol, a naturally occurring antioxidant, can help regulate these processes and improve patient outcomes.

The research demonstrates that RSV treatment significantly decreases PAD4 gene expression and lowers TNF-α cytokine release in NB4 cells, both of which are critical in ETosis. Using advanced tools such as fluorescence microscopy, flow cytometry, PCR, and ELISA, her team confirmed RSV’s ability to suppress ETosis. These findings suggest that Resveratrol could potentially reduce bleeding risks and treatment failure in Acute Promyelocytic Leukemia (APL) patients by limiting ETosis-driven complications.

---

🌟 Key Highlights from the Presentation

·         ETosis and NETosis play a major role in cancer spread and thrombosis.

·         Resveratrol (RSV) acts as a natural inhibitor of ETosis in NB4 cell lines.

·         RSV treatment led to a reduction in PAD4 expression and TNF-α cytokine levels.

·         Advanced research methods validated RSV’s therapeutic potential.

·         The study points to new pathways for improving APL treatment outcomes.

---

👩‍⚕️ About Dr. Minoo Shahidi

Dr. Shahidi is a distinguished Immunohematologist specializing in cancer, angiogenesis, and NETosis. She earned her PhD from Surrey University, UK, and currently serves as an Associate Professor at the Department of Hematology and Blood Banking, Iran University of Medical Sciences. Her extensive research has contributed significantly to the understanding of hematologic malignancies and inflammatory processes.

---

📅 Event Details

Event Name: International Conference on Cancer Science and Research

📍 Venue: Village Hotel Changi, 1 Netheravon Rd, Singapore 508502 & Online
🌐 Website: cancer.miconferences.com
📝 Abstract Submission: Submit Here
✅ Register Now: Click Here

📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448 | WhatsApp: +1 (424) 377 0967
🐦 Follow on X: @CancerWorldConf

---

#CancerConference2025 #APLResearch #ResveratrolStudy #NETosis #ETosis #OncologyInsights #HematologyUpdates #CancerWorldConf #DrMinooShahidi #CancerTreatment

Rethinking Cancer Theory: Dr. Chanda Siddoo-Atwal’s Groundbreaking Insights

The International Conference on Cancer Science and Research (November 17–19, 2025, Singapore & Online) will feature a thought-provoking oral virtual presentation by Dr. Chanda Siddoo-Atwal, President and Primary Biochemist of Moondust Cosmetics Ltd., Canada. Her talk, “Is Cancer Theory Incomplete?”, challenges long-standing assumptions in cancer biology and opens up a new perspective on carcinogenesis.

🌟 Key Takeaways from the Presentation

·         Traditional cancer theory, largely centered on DNA mutations, may not fully explain how all cancers develop.

·         Research shows that uncontrolled apoptosis (programmed cell death) can directly lead to tumor formation.

·         Animal and human studies suggest that increased apoptosis in tissues may accelerate cancer development.

·         Not all carcinogens are mutagens, pointing to alternate pathways in cancer initiation.

·         A proposed two-step apoptotic model highlights:

1.        Initial rise in apoptosis (from genetics, stress, or mutation).

2.        Development of apoptosis resistance, disrupting normal cell balance and fueling abnormal growth.

·         Early findings indicate these steps may be reversible with targeted apoptotic therapies, offering new hope for treatment.

👩‍🔬 About Dr. Chanda Siddoo-Atwal

Dr. Siddoo-Atwal earned her Ph.D. in Applied Sciences at Simon Fraser University, with research carried out at the BC Cancer Research Centre, followed by a post-doctoral fellowship at the Medical College of Wisconsin. With deep expertise in carcinogenesis and radiation-induced cancers, she has authored books, contributed to global oncology textbooks, and co-authored clinical texts. Through Moondust Cosmetics Ltd., she pioneers sunscreen research targeting apoptotic sunburn linked to skin cancer, bridging science with practical prevention.

📌 Event Information

·         Event Name: International Conference on Cancer Science and Research

·         Dates: November 17–19, 2025

·         Venue: Village Hotel Changi, Singapore & Online

·         🌐 Website: cancer.miconferences.com

·         📝 Register Here

·         📤 Submit Abstract

·         📩 Email: cancer@mathewsconference.com

·         📞 Phone: +1 (312) 462-4448 | WhatsApp: +1 (424) 377 0967

·         Follow updates on X: @CancerWorldConf

#CancerTheory #CancerScience2025 #Carcinogenesis #ApoptosisResearch #OncologyInnovation #CancerConference #CancerBiology #CancerTreatment #HybridConference #OncologyUpdates